Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Andrew Stewart

Showing results (131-140 of 148) with videos related to

Pageof 15
Sort By:
International Journal of Molecular Sciences|March 25, 2017
PAMAM Dendrimers Cross the Blood-Brain Barrier When Administered through the Carotid Artery in C57BL/6J MiceBhairavi Srinageshwar, Sarah Peruzzaro, Melissa Andrews, et al.
The Journal of Laryngology and Otology|January 22, 2024
Impact of primary care triage using the Head and Neck Cancer Risk Calculator version 2 on tertiary head and neck services in the post-coronavirus disease 2019 periodJiak-Ying Tan, Christopher John Callaghan, Alexander William Lewthwaite, et al.
Plos One|September 3, 2010
Rapid identification of genetic modifications in Bacillus anthracis using whole genome draft sequences generated by 454 pyrosequencingPeter E Chen, Kristin M Willner, Amy Butani, et al.
Cost Effectiveness and Resource Allocation : C/E|November 19, 2015
Fractional flow reserve (FFR) versus angiography in guiding management to optimise outcomes in non-ST segment elevation myocardial infarction (FAMOUS-NSTEMI) developmental trial: cost-effectiveness using a mixed trial- and model-based methodsJulian Nam, Andrew Briggs, Jamie Layland, et al.
The Journal of Pharmacology and Experimental Therapeutics|July 28, 2004
ABT-963 [2-(3,4-difluoro-phenyl)-4-(3-hydroxy-3-methyl-butoxy)-5-(4-methanesulfonyl-phenyl)-2H-pyridazin-3-one], a highly potent and selective disubstituted pyridazinone cyclooxgenase-2 inhibitorRichard R Harris, Lawrence Black, Sekhar Surapaneni, et al.
Nature|October 5, 2012
Adenoma-linked barrier defects and microbial products drive IL-23/IL-17-mediated tumour growthSergei I Grivennikov, Kepeng Wang, Daniel Mucida, et al.
Cancer Research|May 21, 2015
NOS Inhibition Modulates Immune Polarization and Improves Radiation-Induced Tumor Growth DelayLisa A Ridnour, Robert Y S Cheng, Jonathan M Weiss, et al.
Science (New York, N.Y.)|November 23, 2013
Commensal bacteria control cancer response to therapy by modulating the tumor microenvironmentNoriho Iida, Amiran Dzutsev, C Andrew Stewart, et al.
Molecular Cancer Research : MCR|June 6, 2019
T-Cell Deletion of MyD88 Connects IL17 and IκBζ to RAS OncogenesisChristophe Cataisson, Rosalba Salcedo, Aleksandra M Michalowski, et al.
Iscience|July 18, 2022
Group 3 innate lymphocytes make a distinct contribution to type 17 immunity in bladder defenceAlexandra M Riding, Kevin W Loudon, Andrew Guo, et al.
Pageof 15

Showing results (131-140 of 148) with videos related to

Sort By:
Pageof 15
International Journal of Molecular Sciences|March 25, 2017
PAMAM Dendrimers Cross the Blood-Brain Barrier When Administered through the Carotid Artery in C57BL/6J MiceBhairavi Srinageshwar, Sarah Peruzzaro, Melissa Andrews, et al.
The Journal of Laryngology and Otology|January 22, 2024
Impact of primary care triage using the Head and Neck Cancer Risk Calculator version 2 on tertiary head and neck services in the post-coronavirus disease 2019 periodJiak-Ying Tan, Christopher John Callaghan, Alexander William Lewthwaite, et al.
Plos One|September 3, 2010
Rapid identification of genetic modifications in Bacillus anthracis using whole genome draft sequences generated by 454 pyrosequencingPeter E Chen, Kristin M Willner, Amy Butani, et al.
Cost Effectiveness and Resource Allocation : C/E|November 19, 2015
Fractional flow reserve (FFR) versus angiography in guiding management to optimise outcomes in non-ST segment elevation myocardial infarction (FAMOUS-NSTEMI) developmental trial: cost-effectiveness using a mixed trial- and model-based methodsJulian Nam, Andrew Briggs, Jamie Layland, et al.
The Journal of Pharmacology and Experimental Therapeutics|July 28, 2004
ABT-963 [2-(3,4-difluoro-phenyl)-4-(3-hydroxy-3-methyl-butoxy)-5-(4-methanesulfonyl-phenyl)-2H-pyridazin-3-one], a highly potent and selective disubstituted pyridazinone cyclooxgenase-2 inhibitorRichard R Harris, Lawrence Black, Sekhar Surapaneni, et al.
Nature|October 5, 2012
Adenoma-linked barrier defects and microbial products drive IL-23/IL-17-mediated tumour growthSergei I Grivennikov, Kepeng Wang, Daniel Mucida, et al.
Cancer Research|May 21, 2015
NOS Inhibition Modulates Immune Polarization and Improves Radiation-Induced Tumor Growth DelayLisa A Ridnour, Robert Y S Cheng, Jonathan M Weiss, et al.
Science (New York, N.Y.)|November 23, 2013
Commensal bacteria control cancer response to therapy by modulating the tumor microenvironmentNoriho Iida, Amiran Dzutsev, C Andrew Stewart, et al.
Molecular Cancer Research : MCR|June 6, 2019
T-Cell Deletion of MyD88 Connects IL17 and IκBζ to RAS OncogenesisChristophe Cataisson, Rosalba Salcedo, Aleksandra M Michalowski, et al.
Iscience|July 18, 2022
Group 3 innate lymphocytes make a distinct contribution to type 17 immunity in bladder defenceAlexandra M Riding, Kevin W Loudon, Andrew Guo, et al.
Pageof 15